EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Rational modification of PROTACs for tumor-selective protein degradation

Zhongliang Fu, Meichen Pan, Chunrong Yang, Hongwei Hou, Jinghong Li

Advanced Drug Delivery Reviews · 2026-03 · 230 · 115775

DOI: 10.1016/j.addr.2026.115775 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-03. Verfasst von Zhongliang Fu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Life Science Academy, Beijing 102209, China; School of Biomedical Sciences, Hunan University, Changsha 410082, China; New Cornerstone Science…. Hauptthemen laut MEDLINE: Neoplasms, Proteolysis, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 224 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that hijack the ubiquitin-proteasome system to catalytically degrade pathogenic proteins. With the ability to target "undruggable" proteins and exert sustained pharmacological effects, PROTACs hold considerable promise for cancer therapy. However, achieving tumor-selective protein degradation remains a central challenge. This review outlines the application of PROTACs in cancer treatment and systematically summarizes emerging strategies to enhance tumor specificity. These approaches leverage hallmark features of tumors, distinctive surface biomarkers and a unique tumor microenvironment (TME), and are broadly categorized into two classes: active targeting, which employs tumor-selective ligands to enrich PROTACs in malignant cells; and conditionally activated strategies, where TME cues either selectively trigger PROTAC prodrugs or induce structural transformations in nanocarriers to enhance drug accumulation at the tumor site. By elucidating these mechanisms, we aim to bridge medicinal chemistry and intelligent nanomedicine, underpinning the tumor-selective protein degradation strategies and offering perspectives on future research directions to improve the biodistribution, safety, and therapeutic efficacy of next-generation PROTACs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProteolysisAntineoplastic AgentsHumansProteolysis Targeting ChimeraAnimalsTumor MicroenvironmentProteasome Endopeptidase Complex

Stichwörter der Autor:innen

Cancer therapyPROTACsProtein degradationTargeted therapy

Substanzen

Proteolysis Targeting ChimeraAntineoplastic AgentsProteasome Endopeptidase Complex

Autor:innen und Institutionen

  • Beijing Life Science Academy, Beijing 102209, China; School of Biomedical Sciences, Hunan University, Changsha 410082, China; New Cornerstone Science Laboratory, Department of Chemistry, Key Laboratory of Bioorganic Pho…
  • Beijing Life Science Academy, Beijing 102209, China; New Cornerstone Science Laboratory, Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing 100084…
  • Beijing Life Science Academy, Beijing 102209, China. Electronic address: houhw@ztri.com.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Fu, Z., Pan, M., Yang, C., Hou, H., & Li, J. (2026). Rational modification of PROTACs for tumor-selective protein degradation. Advanced Drug Delivery Reviews, 230, 115775. https://doi.org/10.1016/j.addr.2026.115775

Vancouver

Fu Z, Pan M, Yang C, Hou H, Li J. Rational modification of PROTACs for tumor-selective protein degradation. Advanced Drug Delivery Reviews. 2026;230:115775. doi:10.1016/j.addr.2026.115775

BibTeX
@article{Fu2026,
  author = {Fu, Zhongliang and Pan, Meichen and Yang, Chunrong and Hou, Hongwei and Li, Jinghong},
  title = {Rational modification of PROTACs for tumor-selective protein degradation},
  journal = {Advanced Drug Delivery Reviews},
  year = {2026},
  volume = {230},
  pages = {115775},
  doi = {10.1016/j.addr.2026.115775}
}
Kostenlos starten →